Singapore Clinical Trial: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Vers... Read More

Clinical Trial: Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07853807) titled 'Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): ... Read More

Clinical Trial: The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07855692) titled 'The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)' on Sept. 28. Bri... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Vers... Read More

Clinical Trial: Wording Approaches to Convey the Strength of Recommendations in Health Guidelines

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07854548) titled 'Wording Approaches to Convey the Strength of Recommendations in Health Guidelines' on Sept. ... Read More

Singapore Clinical Trial: A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2)

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety a... Read More

Singapore Clinical Trial: A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (NEBULA-1)

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and ... Read More

Singapore Clinical Trial: A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6)

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD01... Read More

Clinical Trial: Trial Without Borders IMPLEMENT-CKD: IMPLEMENTation of Evidence-Based SGLT2i to Reduce Global Burden of Cardiovascular and Chronic Kidney Disease

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07854808) titled 'Trial Without Borders IMPLEMENT-CKD: IMPLEMENTation of Evidence-Based SGLT2i to Reduce Globa... Read More

Singapore Clinical Trial: A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or without Bevacizumab in Comparison to Active Observation with or without Bevacizumab as Maintenance Treatment in Participants with Newly Diagnosed FIGO Stage III/IV Non-Homologous Recombination Deficient Ovarian Cancer

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or wi... Read More

• ««
• «
• 1271
• 1272
• 1273
• 1274
• 1275
• 1276
• 1277
• 1278
• 1279
• 1280
• »
• »»